1620 Beacon Place
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in innovative delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada and Israel. The company's mission is to improve people's lives by redefining how medicines are delivered and experienced.
CEO: Robert Davidson
COO: Jessica Rousset
CFO: Alex Katz
30 articles with CURE Pharmaceutical
In the cannabis sector of drug development, there is a movement happening. And Rob Davidson, chief executive officer of CURE Pharmaceuticals is making sure his company is ready for the next steps.
3/15/2019The scandal, dubbed Operation Varsity Blues, revolves around dozens of wealthy parents paying a college consultant to help cheat on entrance exams and falsify student athlete profiles, as well as bribing coaches at a number of prestigious universities.
Shares of CURE Pharmaceutical jumped more than 15 percent Monday ahead of news that the company became the first and only oral thin film company to gain a license from the U.S. Drug Enforcement Agency to manufacture pharmaceuticals using both cannabis plant extracts and synthetic cannabidiol.
The DEA has reclassified GW Pharmaceutical’s cannabidiol epilepsy treatment Epidiolex as a Schedule V product, which will clear the way for commercialization within the next six weeks.
CURE grants cannabis leader rights to its proprietary drug delivery technology in markets around the world
Therapix Biosciences Signs Term Sheet for the Transfer of Non-Pain Cannabinoid-Based Drug Pipeline Assets to Cure Pharmaceutical
Therapix Biosciences Ltd. announced that it has signed a non-binding term sheet with CURE Pharmaceutical for the transfer to CURE of the non-pain assets of Therapix, subject to the fulfillment of the certain conditions.
CURE Pharmaceutical announced that it has signed a term sheet with Therapix Biosciences Ltd.
Cure Pharmaceutical Enters Into Product Development Agreement With Therapix Biosciences To Develop Cannabinoid-Based Product for Sleep Disorders
This agreement is an extension of the recently announced partnership between CURE, Therapix and Israel’s Assuta Medical Centers, Ltd.
CURE Pharma Launches New Academic Partnership Program Providing The Company’s Proprietary Curefilm For More Humane And Effective Animal Research
CURE Pharma Subsidiary, Oak Therapeutics, Completes Critical Milestone In Phase I Of NIH Grant To Develop Oral Dissolvable Strip For Tuberculosis
CURE Pharma Enters Partnership To Distribute New Erectile Dysfuntion Drug Using Company’s Proprietary CureFilm Into Asian Market
CURE Pharma And Therapix Signs MOU With Israel’s Assuta Medical Centers To Develop First-In-Class Therapeutic Products In Fields Of Personalized Medicine & Cannabinoids
CURE Pharma & Therapix Signs MOU With Israel's Assuta Medical Center To Develop First-In-Class Therapeutic Products In Fields Of Personalized Medicine & Cannabinoids
Leading OTF Manufacturer CURE Pharma Comments On New Report Showing Exponential Growth In Thin Film Drug Manufacturing Market
CURE Pharma And CannaKids Announce Research Collaboration With Technion-Israel Institute Of Technology On Cancer-Fighting Cannabinoids
CURE Pharma Receives First Purchase Order Stemming From Product Development And License Agreement With Pharmaceutical Company, Meroven
CURE Pharma Announces Crosslink Patent For Covering Company’s Proprietary Curefilm Drug Delivery Technology